Melanoma is a type of cancer that originates from melanocytes, the cells responsible for producing skin pigment, and is known ...

Black Diamond Therapeutics has deprioritized one of its two clinical-stage lung cancer contenders, jettisoned two executives ...

Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall ...

Key mechanism of resistance to BRAF-targeted melanoma therapy discovered. Potential for developing new cancer therapies with high efficacy by regulating polyamine biosynthesis to suppress resistance.

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

Baton Rouge Head Start serves less than half the 3- and 4-year-olds it served pre-pandemic. To recover, early childhood ...

Pasithea Therapeutics today announced safety, tolerability, pharmacokinetic (PK) and preliminary efficacy data from the first 2 cohorts of patients (n=6) in its Phase 1 clinical trial of PAS-004, ...

On Thursday, Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced safety, tolerability, pharmacokinetic (PK), and preliminary ...

Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a ...

Headline inflation has fallen into the Reserve Bank's 2 to 3 per cent target for the first time in three years. Here's why it won't mean an early rate cut.

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer ...